吉西他滨联合顺铂与长春瑞滨联合顺铂治疗晚期肺腺癌的比较  

Clinical observation of gemcitabine with cisplatin and navelbine with cisplatin in the treatment of patients with advanced lung adenocarcinoma

作　　者：纪春祥[1] 郝延璋[1] 李绵利[1] 于泽顺[1] 

机构地区：[1]滨州医学院附属医院肿瘤科,滨州市256603

出　　处：《滨州医学院学报》2009年第1期32-33,共2页Journal of Binzhou Medical University

摘　　要：目的观察比较吉西他滨联合顺铂与长春瑞滨联合顺铂治疗晚期肺腺癌的疗效及不良反应。方法回顾性分析86例经病理诊断的晚期肺腺癌患者，吉西他滨＋顺铂（GP）组50例，长春瑞滨＋顺铂（NP组）36例。GP组：吉西他滨（泽菲）1000mg／m^2，静脉点滴，第1、8天；顺铂（DDP）25mg／m^2，静脉点滴，第1～3d，每21d为一周期。NP组：长春瑞滨（国产）25mg／m^2，静脉点滴，第1、8天；顺铂用法同上，每21d为一周期。连用2个周期以上。结果GP组总有效率（CR＋PR）为48．0％，一年生存率34．6％为（17／50）；NP组总有效率为25．0％，一年生存率为33．3％（12／36），两组间有效率比较差异有显著性（P〈0．05），一年生存率比较差异无显著性（P〉0．05）；最常见的不良反应是骨髓抑制和胃肠道反应，骨髓抑制两组间比较差异有统计学意义，胃肠道反应两组间比较差异无统计学意义。结论吉西他滨联合顺铂可以成为肺腺癌首选方案，但注意骨髓毒副反应。Objective To study the efficacy , toxicity and side effects of gemcitabine （ GEM） or navelbine （ NVB ） combined with cisplatin （ DDP） in patients with advanced lung adenocarcinoma. Methods 86 patients diagnosed by pathology or cytology were divided into GP group （GEM 1000 mg/m^2 ,the 1st and 8th days,and DDP 25 mg/m^2 ,1-3 days in 50 cases , each cycle was 21 days） and NP group （ NVB 25 mg/m^2, d1,8 and DDP 25 mg/m^2, 1-3 days in 36 cases, each cycle was 21 days ） . Results The efficacy of group GP and NP group was 48.0 % and 25.0 % respectively. Significant difference （P 〈 0. 05 ） appeared between two groups from the view of accounting. Finally the 1-year survival rate was 34.6% （17/50） in GP group , 33.3% （12/36） in NP group. There was no significant difference （ P 〉 0. 05 ） between two groups. The main side effects were myelosuppression and gastrointestinal reactions. There was significant difference （ P 〈 0. 05 ） between two groups in myelosuppression but not in gastrointestinal reactions. Conclusion GP is currently one of the first choices for the treatment of lung adenocarcinoma.

关 键 词：吉西他滨 长春瑞滨 顺铂 肺腺癌 化疗 

分 类 号：R732.2[医药卫生—肿瘤]